Efficacy and Safety of S-amlodipine 2,5 mg and 5 mg in Hypertension Patients
Status:
Completed
Trial end date:
2017-02-14
Target enrollment:
Participant gender:
Summary
s-amlodipine besylate 2,5 mg tablet will be administered to patients have not received any
hypertension treatment before or have received any of anti-hypertensive mono-therapy for the
first four weeks of treatment. By increasing dose, s-amlodipine besylate 5 mg tablet will be
administered for the last four weeks (4-8 weeks).